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Abstract
Fulvestrant is a representative pure antiestrogen and a Selective Estrogen Receptor Down-regulator (SERD). In contrast to
the Selective Estrogen Receptor Modulators (SERMs) such as 4-hydroxytamoxifen that bind to estrogen receptor a (ERa)a s
antagonists or partial agonists, fulvestrant causes proteasomal degradation of ERa protein, shutting down the estrogen
signaling to induce proliferation arrest and apoptosis of estrogen-dependent breast cancer cells. We performed genome-
wide RNAi knockdown screenings for protein kinases required for fulvestrant-induced apoptosis of the MCF-7 estrogen-
dependent human breast caner cells and identified the c-Src tyrosine kinase (CSK), a negative regulator of the oncoprotein
c-Src and related protein tyrosine kinases, as one of the necessary molecules. Whereas RNAi knockdown of CSK in MCF-7
cells by shRNA-expressing lentiviruses strongly suppressed fulvestrant-induced cell death, CSK knockdown did not affect
cytocidal actions of 4-hydroxytamoxifen or paclitaxel, a chemotherapeutic agent. In the absence of CSK, fulvestrant-induced
proteasomal degradation of ERa protein was suppressed in both MCF-7 and T47D estrogen-dependent breast cancer cells
whereas the TP53-mutated T47D cells were resistant to the cytocidal action of fulvestrant in the presence or absence of CSK.
MCF-7 cell sensitivities to fulvestrant-induced cell death or ERa protein degradation was not affected by small-molecular-
weight inhibitors of the tyrosine kinase activity of c-Src, suggesting possible involvement of other signaling molecules in
CSK-dependent MCF-7 cell death induced by fulvestrant. Our observations suggest the importance of CSK in the
determination of cellular sensitivity to the cytocidal action of fulvestrant.
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Introduction
Approximately 70% of breast cancers express estrogen receptor
a (ERa), and most of these ERa-positive primary tumors depend
on estrogen signaling for their growth and survival [1]. Endocrine
therapy aims to shut off estrogen signaling in ERa-positive breast
cancer cells to halt cell proliferation and/or to induce cell death
[2–7]. Two types of antiestrogens with distinct mechanisms of
actions have been used for this purpose: Selective Estrogen
Receptor Modulators (SERMs) and the Selective Estrogen
Receptor Down-regulators (SERDs). The SERMs, represented
by tamoxifen or raloxifene, bind to ERa as partial agonist or
antagonists in a manner dependent on target tissues [8–10]. On
the other hand, the SERDs, represented by fulvestrant, bind to
ERa and induce rapid proteasomal degradation of ERa protein
[11]. Unfortunately, the benefit of endocrine therapy is seriously
limited by resistance of tumors against antiestrogens [12], and a
large number of studies have proposed molecular mechanisms
behind the endocrine therapy resistance of human breast cancer
cells. When activated by agonistic ligands, ERa functions as a
transcription factor and affects expression of thousands of genes in
human breast cancer cells [13–15]. In addition, ERa initiates
rapid intracellular signaling [16] through phosphorylation of
membrane receptor kinases, including insulin-like growth factor I
receptor (IGF-IR) [17], epidermal growth factor receptor (EGFR)
[18], and HER2/ERBB2 [19]. ERa also interacts with other
signaling kinases and adaptor molecules such as c-Src [20], Shc
[21], PAK1 [22], DLC1 [23,24], PELP1/MNAR [22,25,26], and
p85 PI3-kinase regulatory subunit [27]. These interactions lead to
activation of downstream signaling kinases such as the p42/44
MAPK and AKT [28], which play critical roles in regulating cell
proliferation and survival. Some of these ERa-activated protein
kinases (e.g., c-Src, PAK1, MAPK, and AKT) phosphorylate ERa
to enhance the genomic actions of ERa. Roles of another network
of signaling pathway involving STAT1, interferon regulatory
factor 1, NF-kB, and their downstream effectors (e.g., caspases and
BCL2 family apoptosis regulators) are also becoming increasingly
evident [29]. Thus, a large body of evidence supports the notion
that a highly complex signaling network is involved in the
mechanism of estrogen actions and possibly the endocrine therapy
resistance of ERa-positive breast cancer cells.
To identify novel components in the signaling network leading
to endocrine therapy resistance, functional screening studies using
the RNAi knockdown technique have been performed by several
laboratories. For example, Iorns et al. [30] transfected MCF-7
human breast cancer cells with an arrayed library of siRNA
oligonucleotides that targeted 779 human kinases and phospha-
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clones, they identified three protein kinases (CDK10, CRK7, and
MAP2K7) required for tamoxifen-induced cell death. Taking a
similar approach of Iorns et al., in the present study we performed
lentivirus-based RNAi knockdown screening experiments covering
the entire human kinases and phosphatases and identified CSK (c-
Src tyrosine kinase) as a novel signaling molecule required for
fulvestrant-induced MCF-7 cell death. Whereas RNAi knockdown
of CSK caused significant resistance to fulvestrant, it did not affect
sensitivities to either tamoxifen or paclitaxel. We provide evidence
that this strong specificity of fulvestrant resistance caused by CSK
knockdown was due to suppression of the fulvestrant-induced
proteasomal degradation of ERa protein, which is not involved in
the mechanisms of actions of tamoxifen or paclitaxel. Our present
study provides important insights into the molecular mechanisms
of the cytocidal action of fulvestrant in human breast cancer cells,
providing evidence of requirement of CSK.
Results
RNAi knockdown of the c-Src Tyrosine Kinase (CSK)
caused resistance of MCF-7 cells to fulvestrant
Our prior studies revealed the critical importance of BIK (a
BH3-only family pro-apoptotic protein) and TP53 (a tumor
suppressor transcription factor necessary for transcriptional
induction of the BIK mRNA transcripts) in fulvestrant-induced
apoptosis of MCF-7 cells [31,32]. To obtain further insights into
the mechanism of fulvestrant actions, we performed RNAi
knockdown screenings to identify additional molecules required
for fulvestrant-induced MCF-7 cell apoptosis. MCF-7 cells grown
in 384-well plates were infected with a library of arrayed
lentiviruses expressing shRNA species targeting the entire RefSeq
collection of know human protein kinases and phosphatases
consisting of 6,560 lentivirus clones [33,34]. Cells were then
exposed to 100 nM fulvestrant for 7 days, and surviving cells were
visualized by crystal violet staining. These screenings revealed that
RNAi knockdown of MAP2K7 or CSK (c-Src tyrosine kinase,
NCBI gene ID=1445) strongly suppress fulvestrant-induced
MCF-7 cell death (Fig. 1A for CSK data; MAP2K7 data not
shown). Since a similar RNAi knockdown project by Iorns et al.
already identified MAP2K7 and several other kinases including
CDK10 as Ser/Thr kinases required for tamoxifen sensitivity of
MCF-7 cells, we focused on the roles of CSK in the cytocidal
action of fulvestrant on MCF-7 cells.
RNAi knockdown of two independent shRNA lentivirus clones
targeting human CSK [The RNAi Consortium Clone
ID=TRCN0000199018 (target sequence, 59-CCACTAAGTCT-
GACGTGTGGA, is in the CSK coding sequence) and
TRCN0000199031 (target sequence, 59-
CCGTCTCTCTTGGACCCACCT, is in the 39-UTR of the
CSK mRNA transcripts); hereafter referred to as shRNA #1 and
#2, respectively] confirmed the requirement of CSK for the
cytocidal action of fulvestrant in MCF-7 cells. When cells were
infected with these shRNA lentiviruses at MOI=4,8 and selected
by puromycin resistance for 48 hours, we observed about 65%–
75% reduction in CSK protein expression (Fig. 1B). The CSK
RNAi knockdown was stable in the infected cells for at least five
passages, within which all experiments in the present study were
performed. Exposure of cells to 100 nM fulvestrant for 7 days
induced massive cell death in mock-infected cells and cells infected
with the pLKO.1 empty lentiviral vector resulted in only
8.160.3% and 8.560.6% surviving cells, respectively (Fig 1C
and Fig. S1). In contrast, MCF-7 cells infected cells the CSK
shRNA lentiviruses showed significant resistance to fulvestrant-
induced death, with 21.561.3% and 35.362.7% surviving cells
after exposure to shRNA #1 and #2, respectively.
To determine whether the CSK knockdown efficiency corre-
lates with the strength of fulvestrant resistance, MCF-7 cells were
infected with a 10-clone panel of shRNA lentiviruses (Table S1),
and their fulvestrant-induced cell death was examined (Fig. S2).
Effective RNAi knockdown of CSK was observed with four
shRNA lentiviral clones whereas three clones as well as pLKO.1
control clones failed RNAi knockdown. Fulvestrant resistance was
observed with the four shRNA lentiviral clones that effectively
knocked down CSK whereas cells infected with the failed lentiviral
Figure 1. RNAi knockdown of CSK in MCF-7 cells causes
resistance to fulvestrant. (A) RNAi knockdown screening reveals
dependence of fulvestrant-induced MCF-7 cell death on CSK. Cells
infected with lentiviruses expressing shRNA to CSK (well is identified by
red circle) survived after 7 days of exposure to 100 nM fulvestrant.
Crystal violet staining of a representative screening plate is shown. (B)
Knockdown of CSK protein expression by shRNA lentiviruses. Cells were
infected with empty lentivirus vector (pLKO.1) or two independent
clones of lentiviruses expressing different shRNA species targeting CSK
shown in Figure 1 (CSK KD#1 and #2) and subjected to Western
blotting quantitation of CSK protein expression (top). Intensities of CSK
protein bands were determined by densitometry as shown in the bar
graph (bottom, mean6SEM of three independent experiments. Asterisk
indicates statistical significance, p,0.05). (C) Infection by lentiviruses
expressing shRNA targeting CSK causes fulvestrant resistance of MCF-7
cells. Cells were infected with empty lentivirus vector (pLKO.1) or two
independent clones of lentiviruses expressing different shRNA species
targeting CSK (CSK KD #1 and #2) and exposed to fulvestrant, or
vehicle for 7 days. % Cell survival (mean6SEM) was determined by
three independent experiments. *, p,0.001 to both mock infected and
pLKO.1-infected controls exposed to fulvestrant). No significant
changes were observed with cell survival ratio of any virus-infected
cells compared to mock infected control.
doi:10.1371/journal.pone.0060889.g001
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killed after 7-day exposure to 100 nM fulvestrant. These results
indicate that CSK is required for fulvestrant-induced MCF-7 cell
death.
RNAi knockdown of CSK does not affect MCF-7 cell
sensitivity to either tamoxifen or paclitaxel
Two different types of antiestrogens are presently used for
endocrine therapy of breast cancer–namely, the SERDs (repre-
sented by fulvestrant) and the SERMs (represented by tamoxifen).
Cross-resistance of breast cancer cells to these distinct types of
drugs is often observed, in both clinical and cell culture settings
[35–37]. To examine whether CSK is required for the cytocidal
effects of tamoxifen, MCF-7 cells were exposed to 4-hydroxyta-
moxifen (4-OHT), which is the biologically active metabolite of
tamoxifen [38]. A 10-day exposure to 1 mM 4-OHT caused
significant MCF-7 cell death although its cytocidal effect was
weaker than that of fulvestrant (Figs. 2A and S3A), in agreement
with previous studies [39,40]. To our surprise, RNAi knockdown
of CSK did not affect the tamoxifen effect at all. These results
indicate that CSK is specifically required for fulvestrant (SERD)-
induced MCF-7 cell death while it is dispensable for the cytocidal
action of tamoxifen (SERM).
To further characterize the specificity of the CSK requirement
for drug-induced MCF-7 cell death, we examined the effects of
RNAi knockdown of CSK on MCF-7 cell sensitivity to paclitaxel,
a widely used chemotherapeutic drug that inhibits dissociation of
microtubule polymers [41]. A 2-day exposure of MCF-7 cells to
varying concentrations of paclitaxel (1–1000 nM) caused massive
cell death in a dose-dependent manner (Figs. 2B and 3SB).
However, RNAi knockdown of CSK failed to affect the cytocidal
effects of paclitaxel. Thus, the drug resistance of MCF-7 cells
infected with shRNA lentiviruses targeting CSK was highly
specific for fulvestrant.
CSK is required for fulvestrant-induced ERa protein
degradation in estrogen-dependent human breast
cancer cells
Fulvestrant causes proteasomal degradation of ERa protein in
breast cancer cells [11,31,35]. High concentrations of 17b-
estradiol (E2), a physiological ligand of ER, also causes
proteasomal degradation of liganded ERa protein [42–44]. Since
strong genetic and phenotypic heterogeneity, including sensitivity
to antiestrogens, has been shown to occur in MCF-7 cell cultures
maintained in different institutions and cell resource repositories
[45–50], we first attempted to confirm that both fulvestrant and
E2 cause proteasome-dependent degradation of ERa protein.
When MCF-7 cells were exposed to 100 nM fulvestrant,
expression of ERa protein was reduced in a time-dependent
manner (Fig. 3A, 3C). Similarly, exposure of hormone-starved
MCF-7 cells to 100 nM E2 caused time-dependent reduction in
ERa protein expression (Fig. 3B, 3C). Under our experimental
conditions, the time-dependent reduction in ERa protein caused
by exposure to fulvestrant and E2 were comparable, with only
35% of ERa protein remained after 6 hours of exposure (Fig. 3C).
It is important to emphasize that the E2-induced reduction in ERa
protein expression was observed only at the highest concentration
of the ligand tested (100 nM; Fig. 3D). In contrast, E2-stimulated
proliferation of MCF-7 cells at only 100 pM [13]. The observed
reduction in ERa protein expression after exposure to both
fulvestrant and E2 did not occur when cells were pre-exposed to
MG132, a wide-spectrum proteasome inhibitor [51] (Figs. 3F–G),
confirming the reported proteasome-dependent nature of fulves-
trant- and E2-induced degradation of ERa protein [52,53].
Exposure to a high concentrations of MG132 (125 nM) caused
increase in ERa protein expression to a level even greater than
cells not exposed to fulvestrant, suggesting the presence of basal
ERa protein turnover (i.e., persistent synthesis and proteasomal
degradation) in MCF-7 cells.
Although fulvestrant and tamoxifen are similar in inhibiting
estrogen signaling, their mechanisms of actions differ. Whereas
fulvestrant cause proteasomal degradation of ERa protein in
breast cancer cells [11,31,35], tamoxifen is known to stabilize ERa
protein [54,55]. To explain the fulvestrant-specific resistance of
the CSK-knockdown MCF-7 cells without affecting their tamox-
ifen sensitivity, we hypothesized that CSK may be required for
fulvestrant-induced proteasomal degradation of ERa protein. To
test this hypothesis, we examined time-dependent degradation of
ERa protein after exposure to 100 nM fulvestrant in MCF-7 cells
infected with pLKO.1 control or CSK shRNA lentiviruses (Fig. 4).
Infection with both CSK shRNA lentiviruses #1 and #2 almost
completely abolished the fulvestrant-induced ERa protein degra-
dation when examined by Western blotting. However, infection
Figure 2. RNAi knockdown of CSK does not affect MCF-7 cell
sensitivity to tamoxifen or paclitaxel. Cells were infected with
empty lentivirus vector (pLKO.1) or two independent clones of
lentiviruses expressing different shRNA species targeting CSK shown
in Figure 1 (CSK KD#1 and #2) and then exposed to 1 mM4 -
hydroxytamoxifen (4-OHT) for 10 days (A) or 1–1000 nM paclitaxel for 2
days (B). Cell viability was determined by crystal violet staining (Fig. S3)
and quantified by spectrophotometry (mean6SEM of three or more
independent experiments).
doi:10.1371/journal.pone.0060889.g002
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fulvestrant effect (Figs. 4A and 4B). To obtain more quantitative
ERa protein data, we repeated this experiment but using ELISA
(Fig. 4C). After exposure to fulvestrant for 6 hours, ERa protein in
pLKO.1-infected control cells was reduced from 37.6561.64 ng/
100 mg total extractable cellular protein to 22.2760.72 ng/
100 mg. On the other hand, ERa expression in cells infected with
CSK shRNA lentiviruses was slightly reduced from
37.4561.48 ng/100 mg to 30.2261.75 ng/100 mg (shRNA #1)
and 39.5560.65 ng/100 mg to 31.6060.77 ng/100 mg (shRNA
#2) (Fig. 4C). Thus, agreeing with the Western blotting data, ERa
expression determined by ELISA was reduced to 33.666.1% of
vehicle-exposed control after 6-hour exposure to 100 nM
fulvestrant in pLKO.1-infected cells. In contrast, cells infected
Figure 3. Both fulvestrant and 17b-estradiol (E2) enhance proteasomal degradation of ERa protein in MCF-7 cells. (A–C) Fulvestrant
(A) and E2 (B) caused time-dependent reduction in ERa protein expression: Western blotting. Intensities of ERa protein bands were determined by
densitometry (C, mean6SEM of three independent experiments. Asterisks indicate statistical significance, p,0.05 to vehicle control). (D, E) E2 dose-
dependent reduction in ERa protein expression. Cells were exposed to varying concentrations of E2 for 6 hours and subjected to Western blotting
analysis of ERa protein (D). Intensities of ERa protein bands were determined by densitometry (E, mean6SEM of three independent experiments.
Asterisk indicates t-test significance p,0.05 to vehicle control). (F–H), Pre-exposure to MG132 dose-dependently prevented reduction in ERa protein
expression caused by fulvestrant (F) and E2 (G). Con, vehicle control (0.1% ethanol). Cells were exposed to varying concentrations of MG132 for 30
minutes and then exposed additionally to fulvestrant or E2 for 6 hours. Intensities of ERa protein bands were determined by densitometry (H,
mean6SEM of three independent experiments. Asterisks indicate statistical significance, p,0.05).
doi:10.1371/journal.pone.0060889.g003
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#1) and 89.56620.44% (shRNA #2) ERa protein expression as
compared to vehicle control at under the same conditions. When
CSK protein was re-expressed in the cells infected with the CSK
shRNA #1 lentivirus by transfection of an expression plasmid, the
fulvestrant-induced degradation of ERa protein was partly rescued
(Fig. S4). However, re-expression of CSK did not reinstate the
fulvestrant-induced MCF-7 cell death (data not shown), presum-
ably due to the transient nature of CSK re-expression from a
plasmid vector. Thus, RNAi knockdown of CSK expression
strongly suppresses the fulvestrant-induced ERa protein degrada-
tion in MCF-7 cells.
To determine whether the suppression of the fulvestrant-
induced ERa protein degradation by RNAi knockdown of CKS
is also observed in another cell culture model, we repeated the
same experiment with T47D human breast cancer cells. Whereas
T47D cells are dependent on estrogen for their proliferation, they
survive in the absence of estrogen signaling due to the loss-of-
function mutation of the p53 tumor suppressor protein [56]. Thus,
when T47D cells were exposed to fulvestrant, cells neither
proliferated nor died (Fig S5A). Expression of ERa protein in
T47D cells infected with the pLKO.1 control lentiviral vector was
strongly diminished upon exposure to 100 nM fulvestrant for 3–
9 hours (Figs. S5C, S5E), reproducing the observation made with
MCF-7 cells (Fig. 2). In contrast, ERa protein was significantly
resistant to degradation in fulvestrant-exposed T47D cells infected
with the CSK-KD#1 shRNA lentivirus (Figs. S5D, S5E), whose
CSK expression was reduced by approximately 70% (data not
shown). The resistance was partly reversed by re-expression of
CSK from an exogenous vector (Fig. S5E). These results indicate
that CSK is required for the fulvestrant-induced ERa protein
degradation in T47D cells even though fulvestrant does not show
significant cytocidal action in this cell line.
Small-molecular-weight inhibitors of c-Src do not affect
fulvestrant-induced MCF-7 cell death or ERa protein
degradation
CSK (c-Src tyrosine kinase) is a protein tyrosine kinase that
phosphorylates the C-terminal regulatory tyrosine of c-Src
oncoprotein, which itself is a protein tyrosine kinase [57].
Phosphorylation by CSK suppresses the kinase activity of c-Src
as well as other Src-family tyrosine kinases, and this is a
physiological mechanism regulating c-Src activity both in mam-
mals and Drosophila [57,58]. Roles of CSK in metastasis of
human cancer cells have also been suggested [58]. c-Src directly
phosphorylates nuclear hormone receptors such as androgen
receptor or ERa, and this phosphorylation is required for steroid
hormone signaling [59–61]. Thus, c-Src links signaling initiated by
the plasma membrane receptor tyrosine kinases such as epidermal
growth factor receptor and steroid hormone signaling [62–64].
To determine whether CSK affects fulvestrant-induced ERa
protein degradation through altering c-Src kinase activity, we
examined effects of small-molecular-weight inhibitors of c-Src
tyrosine kinase on fulvestrant-induced MCF-7 cell death and ERa
degradation. PP1 is a relatively specific inhibitor of c-Src although
it also inhibits tyrosine kinase activities of c-Kit and Bcr-Abl [65].
AZD0530 (a.k.a. saracatinib) selectively inhibits c-Src and Bcr-Abl
kinases [66–69]. We reasoned that, if CSK is required for
fulvestrant-induced cell death or ERa protein degradation through
suppression of c-Src, inhibition of c-Src tyrosine kinase by
chemical inhibitors would pharmacologically mimic CSK activa-
tion and show the opposite effect of CSK knockdown-namely,
enhanced MCF-7 cell sensitivity to fulvestrant actions. However,
by our hands, neither PP1 (0.5–10 mM) nor AZD0530 (0.1–2 mM)
significantly affected the fulvestrant-induced MCF-7 cell death
(Fig. S6). These c-Src inhibitors did not affect the fulvestrant-
induced ERa protein degradation, either (Fig. 5). Repeated
experiments with reduced fulvestrant concentrations or shorter
exposure times did not reveal any effects of PP1 or AZD0530 (data
Figure 4. CSK is required for fulvestrant-induced ERa protein
degradation in MCF-7 cells. (A, B) RNAi knockdown of CSK protein
expression caused resistance of intracellular ERa protein to fulvestrant-
induced degradation: Western blotting. Cells were infected with control
(pLKO.1) or two CSK-knockdown shRNA lentivirus clones and subjected
to exposure to fulvestrant. Expression of ERa protein was determined
by Western blotting at varying time points of exposure (A). Intensities of
ERa protein bands were determined by densitometry (B, mean6SEM of
three independent experiments. Asterisk indicates statistical signifi-
cance, p,0.05). (C) Similar experiments as shown in panels (A, B) were
performed, but amounts of ERa protein in total cellular protein were
determined by ELISA (mean6SEM of three independent experiments; *,
p,0.05 to vehicle control; #,p ,0.05 to pLKO.1-infected cells exposed
to fulvestrant for the same period).
doi:10.1371/journal.pone.0060889.g004
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these compounds was confirmed by strong suppression of
epidermal growth factor-induced phosphorylation of Tyr416, a
well-accepted hallmark of c-Src activation [58,70–73] (Fig. S7).
Interestingly, c-Src kinase activity was not significantly enhanced
in the MCF-7 cells whose CSK expression was suppressed by
RNAi knockdown (Fig. S7C), suggesting that c-Src regulation by
CSK may have been replaced by other mechanisms.
Discussion
Activation of ERa by E2 triggers assembly of an active
transcription complex, which in turn signals polyubiquitination
and proteasomal degradation of the liganded ERa protein [44,74–
80]. Chu et al. reported that the E2-triggered proteasomal
degradation of ERa protein in MCF-7 cells were enhanced by
activation of c-Src [81]. Binding of fulvestrant to ERa also causes
proteasomal degradation although it is not associated with
transcriptional activation. Because the fulvestrant-triggered ERa
protein degradation is 10 times faster than that triggered by E2 in
MCF-7 cells [82], mechanisms of the ERa protein degradation
invoked by these two ligands may significantly differ. Our present
study provided evidence that CSK, the negative regulator protein
tyrosine kinase of c-Src, is required for fulvestrant-triggered ERa
protein degradation in MCF-7 cells, which appears to be opposite
to the report of Chu et al. [81]. However, the apparent lack of c-
Src activation in the MCF-7 cells whose CSK expression was
stably suppressed by RNAi knockdown (Fig. S7) may suggest that
c-Src might be regulated by other mechanisms in the absence of
CSK in these cells. Rengifo-Cam et al. demonstrated activation of
c-Src by 48-hour adenoviral overexpression of a dominant-
negative CSK in human colorectal cancer cells [58]. Since our
present study was performed using stable CSK-knockdown
cultures of MCF-7 cells, transient activation of c-Src, if any, could
have been suppressed by compensating mechanisms. Our attempts
to suppress the intracellular CSK actions by dominant-negative
CSK as reported by Rengifo-Cam et al. were unsuccessful due to
nonspecific induction of apoptosis of MCF-7 cells, which express
Figure 5. PP1 or AZD0530 tyrosine kinase inhibitors had no effect on ERa protein degradation in MCF-7 cells. In panels (A) and (B),
ERa protein expression after 6-hour exposure to 100 nM fulvestrant in the presence of PP1 or AZD0530 was determined by Western blotting (A) and
ELISA (B, mean6SEM of three or more independent experiments. Asterisks indicate statistical significance, p,0.05, to fulvestrant-only group). In
panels (C) and (D), fulvestrant concentration was reduced as indicated, and ERa protein expression after 6-hour exposure in the presence of PP1 or
AZD0530 was determined by Western blotting (C). Panel (D) shows a typical densitometric quantitation of the ERa protein band. Three
independently performed experiments did not show statistically significant effects of PP1 or AZD0530.
doi:10.1371/journal.pone.0060889.g005
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ER+/PR+/HER2- breast cancers [56,83].
In MCF-7 cells, fulvestrant mobilizes ERa into the nuclear
matrix in a manner dependent on interactions between the helix
12 domain of ERa and cytokeratins 8 or 18 [75,84–86].
Mobilization of ERa to nuclear matrix is necessary for poly-
ubiquitination of ERa protein by a mechanism involving the
NEDD8 ubiquitin-like protein and the Uba3-containing NEDD8-
activating enzyme [87] and subsequent degradation by the 26S
proteasome [85]. Using a panel of kinase inhibitor/activator
chemicals, Marsaud et al. observed that protein kinase C is an
enhancer of the fulvestrant-induced proteasomal ERa degradation
in MCF-7 cells whereas protein kinase A, MAPKs, and
phosphatidyl-inositol-3-kinase act as suppressors [82]. Tsai et al.
also reported that forskolin, a potent activator of protein kinase A,
prevents fulvestrant-induced ERa protein degradation in MCF-7
cells [88]. Thus, the signaling involving protein kinases seems to
have significant roles in regulating the fulvestrant-induced
proteasomal ERa protein degradation in breast cancer cells.
Our finding that CSK is required for this fulvestrant action
provides additional insights into how the kinase/phosphatase-
mediated intracellular signaling network in human breast cancer
cells is closely linked to antiestrogen sensitivity.
A number of previous studies including ours [35] isolated
fulvestrant-resistant variants of MCF-7 cells after long-term
exposure of the polyclonal MCF-7 cell culture to fulvestrant.
These studies agree that the fulvestrant resistant variants isolated
with this approach did not depend on estrogen signaling because
other signaling pathways (e.g., EGF receptor, ERK1/2, c-Met,
and AKT [89–92]) supported their proliferation and survival. In
these fulvestrant resistant variants, the fulvestrant-induced ERa
protein degradation was intact. By siRNA transfection-based
RNAi knockdown screenings generating synthetic resistance to
tamoxifen, Iorns et al. identified CDK10, CRK7, and MAP2K7
as kinases necessary for tamoxifen sensitivity of MCF-7 cells [30].
Again, knockdown of any of these three kinases caused estrogen
insensitivity in MCF-7 cells. Our shRNA lentivirus-based RNAi
knockdown screenings generating synthetic resistance to fulves-
trant identified MAP2K7 and CSK as kinases necessary for
fulvestrant-induced MCF-7 cell death. Independent identification
of MAP2K7 as a kinase required for sensitivities of both tamoxifen
(Iorns et al. [30]) and fulvestrant (our present study) supports
validity of the RNAi knockdown screenings performed in our
present study. Since MAP2K7 knockdown did not affect the
fulvestrant-induced proteasomal degradation of ERa protein (data
not shown), CSK is a unique protein whose knockdown in MCF-7
cells does not cause estrogen insensitivity but leads to drug
resistance due to cancellation of the induced ERa protein
degradation.
Details of the link between CSK knockdown and cancellation of
the fulvestrant-induced proteasomal ERa degradation remain to
be determined. Attempts made in our present study did not
establish roles of c-Src in the requirement of CSK for the
fulvestrant-induced ERa protein degradation although the possi-
ble involvement of c-Src in this mechanism cannot be denied. As
CSK directly phosphorylates not only c-Src but also the
transcription factor [93] and the ATP-activated P2X3 receptor
[94], these non-Src CSK substrates might also be involved in the
fulvestrant-induced ERa protein degradation. In this context, it is
interesting that phosphorylation of c-Jun at Tyr26 and Tyr170 by
CSK causes ubiquitination and proteasomal degradation of the c-
Jun protein [93].
In summary, our present study identified CSK as a novel
protein tyrosine kinase required for the fulvestrant-induced
proteasomal degradation of ERa protein in MCF-7 cells. RNAi
knockdown of CSK caused specific resistance to fulvestrant
without affecting MCF-7 cell sensitivities to tamoxifen or
paclitaxel, suggesting possible importance of CSK for better
understanding of the mechanisms of the cytocidal action of
fulvestrant in human breast cancer cells.
Materials and Methods
Chemicals
Fulvestrant (Faslodex
H/ICI 182,780; research-grade pure chem-
ical) and PP1 were purchased from Tocris (Ellisville, MO). Crystal
violet, 4-Hydroxytamoxifen, paclitaxel, and MG132 were from
Sigma (St. Louis, MO). Puromycin hydrochloride and 17a-
Estradiol was from Calbiochem (Gibbstown, NJ). AZD0530 was
obtained from Selleck Chemicals Co. (ShangHai, China).
Recombinant human epidermal growth factor (EGF) was
purchased from R&D Systems (Minneapolis, MN).
Cell Culture
MCF-7 human breast cancer cell culture (BUS stock) was
provided by C. Sonnenschein and A. M. Soto (Tufts University)
[95,96], and its fulvestrant-sensitive monoclonal subline (W2) was
described in our recent study [35]. Our present study was
performed using the W2 clone of MCF-7 cells. T47D human
breast cancer cells were purchased from ATCC (Manassas, VA).
All cells were maintained in Dulbecco’s MEM (DMEM) supple-
mented with 5% FCS (HyClone, DEFINED grade; Thermo
Scientific, Waltham, MA) in 10% CO2 at 37 uC. To examine ERa
protein degradation induced by 17a-estradiol, subconfluent cells
were washed three times with phenol red-free DMEM (containing
no serum) and incubated in the last wash medium for 60 minutes
at 37 uC. Medium was then replaced by phenol red-free DMEM
supplemented with 5% charcoal/dextran-stripped FCS (HyClone)
and hormone-starved for another 24 hours before exposure to
17a-estradiol [13].
shRNA Lentivirus Production and Infection
Lentiviruses expressing shRNA species targeting specific human
mRNA transcripts were produced using the pLKO.1 vector
harboring the puromycin-resistance marker following published
protocols [33]. Subconfluent HEK293T packaging cells growth in
96-well plates were transfected with arrayed, pLKO.1-based
shRNA expression plasmids for human kinome screening (6,560
protein kinases and phosphatases) obtained from The RNAi
Consortium (Broad Institute, Cambridge, MA) with the expression
plasmids for VSV-G surface antigen and the core lentiviral
genome. For infection, 5 610
3 cells were seeded into wells of 96-
well plate and allowed to attach for 24 hours. Cells (5,10 610
4
cells/well)were infected with lentiviruses (4610
4 IU; MOI=4,8)
in the presence of 8 mg/ml polybrene under 1,200 x g gravity by
spinning for 60 minutes. Medium was changed 48 hours after
infection, and successful infected cells were selected by puromycin
(2.5 mg/ml) for 48 hours.
Cell Viability and Crystal Violet Staining
Cell viability was assessed by crystal violet staining. Cells grown
in 96-well plate were washed with PBS twice and then fixed with
12% formaldehyde. After 10 minutes incubation at room
temperature, cells were completely dried and stained with 1%
crystal violet for 5 minutes. Stained cells were washed with tap
water and subjected to spectrophotometric quantitation (OD
590 nm) using SpectraMax M5 (Molecular Devices, Sunnyvale,
CA).
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Western blotting was performed as we previously described
[97]. Briefly, cells were washed with ice cold PBS and lysed with a
RIPA buffer (150 mM NaCl, 25 mM Tris HCl pH 7.6, 1% NP-
40, 1% sodium deoxycholate, 0.1% SDS). Protein concentration
was determined by bicinchoninic acid (BCA) protein assay kit
(Pierce, Rockford, IL) with BSA as a standard. 80 mg of total
cellular protein was separated on 7.5% Tris-HCl polyacrylamide
gels and transferred to PVDF membranes (Bio-Rad, Richmond,
CA). The membranes were incubated for 1 h with 5% dry skim
milk in PBST buffer (PBS containing 0.05% tween 20) to block
nonspecific binding and then incubated with primary antibodies
(x1000 dilution) overnight at 4 uC. The primary antibodies were:
anti-human actin (goat IgG, sc.-1616/I-19, Santa Cruz Biotech-
nology, Santa Cruz, CA), anti-human ERa (rabbit IgG, sc-542/
MC-20 and sc-544/G-20, Santa Cruz Biotechnology), and anti-
human CSK (goat IgG, ab744–100, Abcam, Cambridge, MA).
The membranes were washed with PBST and then incubated with
peroxidase-conjugated secondary antibodies (donkey anti-goat
IgG or goat anti-rabbit IgG, x3000 dilution, Santa Cruz
Biotechnology) for 1 h at room temperature. All antibodies were
diluted in 1% dry skim milk in PBST buffer. Protein bands were
visualized by enhanced chemiluminescence (GE Healthcare,
Piscataway, NJ) using Kodak BioMax MR films (Perkin Elmer,
Waltham, MA). Signal intensities of protein bands were quanti-
tated by densitometry from at least three independent experiments
using ImageQuant system (GE Healthcare).
Phosphorylation of c-Src was examined using the Odyssey
infrared imaging system (LI-COR Biosciences, Lincoln, Nebraska)
as previously described [98] using rabbit anti-phosphorylated
human c-Src polyclonal antibody (P-Tyr416, #2101, Cell
Signaling Technology, Danvers, MA) and mouse anti-human c-
Src monoclonal antibody (IgG1, sc.-32789, Santa Cruz Biotech-
nology) as primary antibodies. Secondary antibodies (IRDye 680
donkey anti-rabbit IgG and IRDye 800 donkey anti-mouse IgG)
were purchased from LI-COR Biosciences. For c-Src kinase
activity assay, c-Src protein was immunoprecipitated using the
anti-human c-Src monoclonal antibody and protein G beads and
subjected to the ProFluor Src family kinase assay (Promega,
Madison, WI) following the manufacturer’s instructions.
ERa ELISA
Cell lysates were prepared with the RIPA buffer, and 100 mgo f
total protein was subjected to ERa ELISA (Active Motif; Carlsbad,
CA) following manufacturer’s instructions. Absorbance at 450 nm
was determined by Synergy HT plate reader (BioTek, Winooski,
VT).
Expression of CSK by transient transfection of an
expression plasmid
An expression plasmid for human full-length CSK (Cat. #
RC210758) and its control vector (pCMV6-ENTRY) was
purchased from OriGene Technologies (Rockville, MD). The
plasmid expressed an open reading frame for human CSK
transcript variant 1 tagged C-terminally with the myc and DDK
epitope peptides and placed under the CMV promoter. Subcon-
fluent cells were transfected with the CSK expression plasmid or
the control plasmid together with an expression plasmid for a
green fluorescence protein (S65T red shift mutant of EGFP) using
TransIT-LT1 transfection reagent following the manufacturer’s
instructions (Mirus Bio, Madison, WI). High transfection efficiency
(.70%) was confirmed by expression of the EGFP observed using
a fluorescence microscope.
Statistics
Values are expressed as mean6SEM of at least three
independent experiments. One-way analysis of variance (ANOVA)
was performed on the values followed by Tukey post-hoc test in
GraphPad PRISM6 statistic software package (GraphPad Soft-
ware, La Jolla, CA).
Supporting Information
Figure S1 RNAi knockdown of CSK in MCF-7 cells
causes resistance to fulvestrant: Crystal violet staining
data. Cells were infected with empty lentivirus vector (pLKO.1)
or two independent clones of lentiviruses expressing different
shRNA species targeting CSK (CSK KD #1 and #2) and
exposed to puromycin, fulvestrant, or vehicle for 7 days.
(PDF)
Figure S2 RNAi knockdown of CSK in MCF-7 cells and
resistance to fulvestrant. (A) Cells were infected with empty
lentivirus vector (pLKO.1) or lentivirus clones expressing different
shRNA species targeting CSK as listed in Table S1 and subjected
to Western blotting quantitation of CSK protein expression. CSK-
KD, CSK knockdown. (B, C) Fulvestrant resistance of MCF-7
cells infected with shRNA lentiviruses targeting CSK. Cells
infected with shRNA lentivirues were exposed to 100 nM
fulvestrant or vehicle for 7 days. (B) Gross appearance of cell
culture after crystal violet staining. (C) Phase contrast microscopic
images. MCF-7 cells expressing CSK (MCF-7 W2 and pLKO.1
infected cells) showed massive apoptotic death after fulvestrant
exposure whereas cells subjected to RNAi knockdown of CSK
survived. MCF-7 cells with CSK knockdown often showed
significant pileup growth appearance as shown in this picture.
(PDF)
Figure S3 RNAi knockdown of CSK does not affect
MCF-7 cell sensitivity to tamoxifen or paclitaxel. Cells
were infected with empty lentivirus vector (pLKO.1) or two
independent clones of lentiviruses expressing different shRNA
species targeting CSK (CSK KD#1 and #2) and then exposed to
1 mM 4-hydroxytamoxifen (4-OHT) for 10 days (A) or 1–1000 nM
paclitaxel for 2 days (B). Cell viability was determined by crystal
violet staining. Quantified data obtained by spectrophotometry of
the stained cells are shown in Fig. 2.
(PDF)
Figure S4 Re-expression of CSK in MCF-7 cells rescues
fulvestrant-induced ERa protein degradation. (A) Dimin-
ished CSK protein expression in MCF-7 cells subjected to
lentiviral RNAi knockdown and re-expression by transfection of
a CSK expression plasmid: Western blotting. MCF-7 cells were
infected with pLKO.1 control lentivirus (lane 1) or the CSK-
KD#1 shRNA lentivirus (lanes 2, 3). The cells infected with the
CSK-KD#1 virus were further subjected to transfection of an
expression plasmid for human CSK (lane 3) or a control plasmid
harboring no insert (lane 2). Expression of CSK protein was
determined by Western blotting 24 hours after transfection. (B)
Time-course of ERa protein expression in MCF-7 cells exposed to
fulvestrant: Western blotting. Intensities of ERa protein bands
were determined by densitometry (C, mean 6 SEM of three
independent experiments. Asterisk indicates statistical significance
(p,0.05) against the control without exposure to fulvestrant (con).
Sharp indicates statistical significance (p,0.05) between CSK
knockdown cells with or without re-expression of CSK1 from a
plasmid.
(PDF)
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fulvestrant-induced ERa protein degradation. (A, B)
Effects of E2 and fulvestrant on proliferation and survival of
T47D cells. Cells were for up to 6 days (A) or 11 days (B) in the
presence or absence of E2 and/or fulvestrant in the medium, and
the live cell numbers in the culture were determined by crystal
violet staining. Note that live cell number was not decreased in the
presence of fulvestrant even though cells were not proliferated in
this condition, either. (C–E) Changes in ERa protein expression in
T47D cells exposed to fulvestrant. T47D cells infected with
pLKO.1 control lentivirus (C) or the CSK-KD#1 shRNA
lentivirus targeting CSK (D) were exposed to 100 nM fulvestrant
or vehicle (ethanol) for 3, 6, or 9 hours (control, no exposure) and
then subjected to Western blotting determination of ERa protein
expression. Intensities of ERa protein bands were determined by
densitometry (E, mean 6 SEM of three independent experiments.
Asterisk indicates statistical significance (p,0.05) against control;
sharp indicates significant differences between the pLKO.1-
infected and the CSK-KD#1 infected cells observed when cells
were exposed to fulvestrant (p,0.05, t-test).
(PDF)
Figure S6 PP1 or AZD0530 tyrosine kinase inhibitors
had no effect on fulvestrant-induced cell death. Cells were
exposed to PP1 (0.1–2 mM, A) or AZD0530 (0.1–2 mM, B) for 30
minutes and then exposed to 100 nM fulvestrant in the presence of
the same c-Src kinase inhibitors for 5 days. Cell viability was
determined by crystal violet staining. Representative crystal violet
staining images are shown. Amounts of stained cells were
determined by spectrometry as shown in the bar graphs (mean
6 SEM of three independent experiments; asterisk indicates
statistical significance p,0.05 against the vehicle control, sharp
indicates significance against the absence of AZD0530).
(PDF)
Figure S7 c-Src phosphorylation and kinase activity in
MCF-7 cells. (A) Fulvestrant does not induce c-Src phosphor-
ylation. MCF-7 cells were exposed to 100 nM fulvestrant or
20 ng/ml EGF for 5, 10, and 30 minutes and subjected to Western
blotting of Tyr416-phosphorylated and total c-Src. (B) Inhibition
of EGF-induced c-Src Tyr-416 phosphorylation by PP1 or
AZD0530. Cells were exposed to 10 mM PP1 or 2 mM AZT for
30 min and then stimulated with 20 ng/ml EGF for another 30
minutes. Phosphorylation of c-Src at tyr416 was determined by
Western blotting. Typical images of three repeated experiments
are shown for panels (A) and (B). Asterisks indicate statistical
significance (p,0.05). (C) c-Src kinase activities in MCF-7 cells. c-
Src was enriched by immunoprecipitation and subjected to kinase
assay (mean 6 SEM of three experiments). 1–3, MCF-7 cells
infected with pLKO.1 control lentivirus exposed to vehicle (1),
10 mM PP1 (2), or 2 mM AZT (3) for 30 min. 4–5, MCF-7 cells
infected with CSK-KD#1 (4) or CSK-KD#2 (5) shRNA
lentiviruses.
(PDF)
Table S1 The TRC collection of shRNA lentiviral clones
targeting human CSK.
(PDF)
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